Schmid Annette C, Byrne Richard D, Vilar Ramón, Woscholski Rüdiger
Department of Biological Sciences, Imperial College London, Exhibition Road, London SW7 2AZ, UK.
FEBS Lett. 2004 May 21;566(1-3):35-8. doi: 10.1016/j.febslet.2004.03.102.
The tumour suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) shares homology with protein tyrosine phosphatases (PTPases). Similarly, bisperoxovanadium (bpV) molecules that are well-established PTPase inhibitors were shown to inhibit PTEN, but at up to 100-fold lower concentrations. The preference and potency of the bpVs towards PTEN was validated in vivo as demonstrated by: (i) an increase of Ser473 phosphorylation of protein kinase B (PKB) at similar low nanomolar doses, (ii) the lack of any effect on the PKB phosphorylation in the PTEN negative cell line UM-UC-3, (iii) the ability to rescue Ly294002-induced phosphoinositide 3-kinase inhibition and (iv) a lack of tyrosine phosphorylation at low nanomolar doses.
肿瘤抑制因子10号染色体缺失的磷酸酶和张力蛋白同源物(PTEN)与蛋白酪氨酸磷酸酶(PTPases)具有同源性。同样,作为成熟的PTPase抑制剂的双过氧钒(bpV)分子已被证明可抑制PTEN,但所需浓度要低100倍。bpV对PTEN的偏好性和效力在体内得到了验证,如下所示:(i)在相似的低纳摩尔剂量下,蛋白激酶B(PKB)的Ser473磷酸化增加;(ii)对PTEN阴性细胞系UM-UC-3中的PKB磷酸化没有任何影响;(iii)能够挽救Ly294002诱导的磷酸肌醇3激酶抑制作用;(iv)在低纳摩尔剂量下没有酪氨酸磷酸化。